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Abstract
Background: Smoking and alcohol increase the risk of head and neck cancer and
affect treatment outcomes. Interventions modifying these behaviors may improve
posttreatment outcomes and survival. We systematically reviewed evidence of the
effectiveness of smoking/alcohol interventions in head and neck cancer and oral
dysplasia.
Methods: The AMED, CINAHL, Embase, MEDLINE, and Web of Science data-
bases were searched for randomized controlled trials (RCTs) of smoking/alcohol
interventions in people with head and neck cancer. A qualitative synthesis of the stud-
ies was conducted.
Results: Three RCTs were identified: 2 smoking interventions and 1 smoking and
alcohol intervention. One intervention, which was comprised of a smoking interven-
tion based on Cognitive Behavioral Therapy and pharmacologic management
compared to usual care, reduced smoking prevalence.
Conclusion: Further research is required into the underlying mechanisms that lead to
cessation and interventions that include both pharmacological and behavioral therapy.
Future RCTs should include suitable control conditions and sufficient power to assess
clinical outcomes.
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1 | INTRODUCTION
Head and neck cancers include cancers of the mouth, sinus,
larynx, nasopharynx, and oropharynx. It is estimated that
10 000 new cases are diagnosed in the United Kingdom each
year1 with >550 000 cases per annum diagnosed world-
wide.2 Survival rates vary according to cancer site. Between
1990 and 2006 the 5-year survival rate for laryngeal cancer
remained the same at 65%. Other forms of head and neck
cancer, such as nasopharyngeal and oropharyngeal cancers,
have seen an increase in 5-year survival rates of 10% and 13%-
14%, respectively, due in part to improved diagnosis and treat-
ment.3,4 Oral epithelial dysplasia (OED) is an oral lesion pre-
ceding the formation of cancerous tissue in 5%-50% of
patients, depending on the type of dysplasia present.5,6
It is estimated that 75% of all head and neck cancers are
caused by tobacco smoking and alcohol consumption.7 One
pooled analysis of 17 case-control studies found the popula-
tion attributable risk for tobacco and alcohol to be 64% for
oral cavity cancer, 72% for pharyngeal cancer, and 89% for
laryngeal cancer.8 The risk factors for OED are not well
understood, although there is evidence that tobacco use and
alcohol consumption relate to increased risk of this premalig-
nant condition.9,10
As well as increasing the risk of disease, evidence also
suggests that smoking and alcohol use can adversely affect
cancer treatment outcomes.11,12 This may be because people
are less likely to respond to treatment if they smoke, result-
ing in a lower rate of survival13 as well as increasing the risk
of treatment side effects.14 Although the mechanisms behind
this are unclear, risk of recurrence and secondary primary
tumors has also been reported to be higher in people who
continue to consume alcohol after their diagnosis.15,16
Evidence of the beneficial effects associated with reduced
tobacco and alcohol use has resulted in a growing interest in
interventions that target these behaviors and in understanding
how these factors can contribute to survival and posttreat-
ment outcomes.16
One previous systematic review on smoking interventions
in head and neck cancer was identified through an initial scope
of the literature.17 However, this review included quasi-
experimental designs and people who had recently quit smoking
within their search strategy and excluded people with premalig-
nant conditions. No reviews on alcohol interventions in people
with head and neck cancer or OED were identified. The purpose
of this review was to examine the effectiveness of smoking and
alcohol cessation interventions on disease-related outcomes,
quality of life (QOL), and smoking and alcohol cessation in
adults with either head and neck cancer or oral epithelial dyspla-
sia. The review has been registered on the Prospective Register
of Systematic Reviews (PROSPERO) database of systematic
reviews, registration number: CRD42016038237.
2 | MATERIALS AND METHODS
The full review protocol has been described in detail
previously.18
2.1 | Eligibility criteria
Eligibility was defined in terms of population, intervention,
control, outcome, and study design. Population: The popula-
tion included adults who have been diagnosed with either
oral epithelial dysplasia or head and neck cancer defined as
cancers of the oral cavity, pharynx, larynx, paranasal sinuses,
nasal cavity, and salivary glands. Intervention: Studies were
included that assessed tobacco or alcohol use reduction or
cessation interventions. Comparison: Intervention compari-
son could include placebo for pharmacological interventions
or standard care for behavioral interventions. Studies that
compared multiple active intervention arms but did not
include a control arm were also included. Outcomes: Studies
were included that reported on any of the primary or second-
ary outcomes of interest. The primary outcomes were
disease-free survival or, for people with oral dysplasia, dis-
ease progression to head and neck cancer. Secondary out-
comes were disease recurrence, disease progression (in head
and neck cancer), QOL, behavioral change, cancer-specific
mortality, second primary cancers (defined as those that ori-
ginated at least 3-cm away from the primary site and
occurred at least 3 years after the last known recurrence), and
all-cause mortality. Study design: Only randomized con-
trolled trials (RCTs) were included in this review.
2.2 | Search strategy
The Cochrane Library, AMED, CINAHL, Embase, MED-
LINE, and Web of Science databases were searched from
their inception to May 23, 2017. The search strategy used in
MEDLINE can be seen in Supporting Information Appendix
S1. The searches were not limited by earliest date or language
of publication. Systematic reviews that were identified
through the search were cross-checked for any studies not
found in the original search and the reference lists of all
included articles were hand searched for additional studies.
The National Institute for Health Research (NIHR) Clinical
Trials gateway was searched to identify any trials that had not
reached publication stage19 and the first 20 pages of Google
Scholar were hand searched for any additional articles.
2.3 | Selection of studies and data extraction
All titles and abstracts were screened independently by 2
reviewers (E.S. and L.R.). Abstracts that potentially met the
inclusion criteria were retrieved and read in their entirety to
assess eligibility. Decisions on inclusions and exclusions
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were recorded (see Figure 1 for flow diagram). Any disagree-
ments were discussed with a third author (R.M.). Two
reviewers extracted the data independently using a standar-
dized, pre-piloted data extraction form created for this
review, then compared results for accuracy. Data were
extracted on publication information, sample characteristics,
intervention type, and results.
2.4 | Assessment of risk of bias
Risk of bias was assessed using the Cochrane Collabora-
tion’s tool,20 which has been updated to reflect the current
study’s review parameter. This tool enabled bias to be
assessed on 6 aspects of trial design and reporting where bias
may be introduced; sequence generation, allocation conceal-
ment, blinding of research participants, blinding of outcome
assessors, completeness of outcome data, and outcome
reporting. Studies were classified for each criterion as having
a low, high, or unclear risk of bias. Any other potential sour-
ces of bias identified by the reviewers were also recorded. A
copy of the table of assessment criteria used for this study is
in Supporting Information Appendix S2.
2.5 | Data analysis
Between-group analyses of the main outcomes are presented
and a qualitative synthesis of all studies was conducted. Due to
the small number of studies found and heterogeneity of the
interventions, a meta-analysis was not deemed appropriate.
The behavioral change techniques used by the trials were
coded using the Behavioral Change Technique (BCT) Taxon-
omy, version 1.21 The BCT Taxonomy allows for more stand-
ardized coding of the behavioral change techniques used in
behavioral change interventions, enabling comparison of tech-
niques used between interventions.
3 | RESULTS
3.1 | Search results
Details of the selection process and reasons for exclusions
are summarized in the inclusion flowchart (Figure 1). The lit-
erature search identified 1089 records. Once duplicates were
removed, 815 records were screened and assessed against the
FIGURE 1 Inclusion flowchart
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eligibility criteria. After exclusion of ineligible studies, 10
studies were included in the review. Of these studies, 7
reported results on multiple cancer sites and did not stratify
results by cancer type. After contacting the study authors,
these were not included in the qualitative synthesis due to
unavailability of the head and neck cancer-specific data.
These studies have been summarized in Supporting Informa-
tion Appendix S2 along with their risk of bias assessments in
Supporting Information Appendix S3. The remaining 3 stud-
ies reported results for head and neck cancer and were
included in the qualitative synthesis.11,22,23 The characteris-
tics of these studies are outlined in Table 1.11,22,23 The 3
included articles were published between 1993 and 2016 and
originated from the United States.
3.2 | Summary of findings
3.2.1 | Participants
Altogether, the 3 trials randomized 384 participants with a
mean age of 58.5 years, 86% of which were men. One trial
included people with either premalignant conditions or head
and neck cancer22 and 2 included people with head and neck
cancer only.11,23 One study recruited participants at any point
after diagnosis. The mean time since diagnosis was 24 months
and ranged from 0 to 282 months.11 A second study did not
limit the sample based on time because treatment or diagnosis;
however, all participants who enrolled were either being
treated with ablation and observation of premalignant lesions
or had undergone treatment for head and neck cancer more
than 5 years previously.22 The third study recruited people
who had been newly diagnosed with head and neck cancer.23
3.2.2 | Interventions
All 3 studies assessed a different form of smoking interven-
tion; 1 study using cognitive behavioral therapy (CBT) com-
bined with pharmacotherapy, 1 study was a clinician-led
intervention, and 1 study using financial incentives. One of
these also included a CBT and pharmacotherapy-based alco-
hol intervention.11 The BCTs that were incorporated into
each intervention are summarized in Table 2.11,22,23 The BCT
Taxonomy coding highlights that different techniques were
used for each intervention with the exception of “coping
skills,” which were used in both the CBT and financial incen-
tive interventions.11,23 Participants were followed up for 6
months in 2 studies11,22 and 12 months in the third study.23
3.2.3 | Comparison
Two studies used some form of usual care as the comparison
group. This was described as “enhanced” usual care11 or
“standardized” usual care.23 “Enhanced usual care” within
the smoking and alcohol trial included brief counseling for
smoking and/or alcohol problems as required along with a
handout for local/state resources for smoking and alcohol
cessation11 Standardized usual care was comprised of provi-
sion of information on the risk of smoking and the benefits
of cessation along with advice to stop smoking.23 The third
study used an “information only” group as the control and
both the intervention and control groups were entitled to free
enrollment in smoking cessation classes.22
3.2.4 | Outcomes
None of the included studies reported on the clinical primary
outcomes of interest (ie, disease-free survival in head and
neck cancer or disease progression in oral epithelial dyspla-
sia). The main outcome variable in all 3 studies was behav-
ioral change measured by self-reported smoking status11,22,23
or alcohol consumption rate.11 Smoking status was con-
firmed by urine cotinine assay in 1 trial23 and either urine
cotinine or exhaled carbon monoxide validation measures in
another.22 One study also reported on QOL as measured by
the 12-item Short Form Health Survey, although no differ-
ence was observed either between groups or between base-
line and 6 month follow-up.22
3.2.5 | Effectiveness of smoking interventions
Only 1 intervention (n 5 184) was found to have an effect
on smoking status. This intervention comprised of a tailored
smoking, alcohol, and depression intervention that used both
nurse-delivered CBT and pharmacologic management in the
form of nicotine replacement therapy and/or bupropion for
smokers, including the patch (n 5 20), gum (n 5 4), inhaler
(n 5 5), bupropion (n 5 6), paroxetine (n 5 6), fluoxetine
(n 5 1), and sertraline (n 5 1).11 Authors found a difference
in smoking cessation rates in the intervention group (47%)
compared with the control group (31%; P < .05). Although
not powered for subgroup analysis, their results showed that
participants treated for comorbid smoking and depression (n
5 64) had higher smoking cessation rates than those in usual
care (51% compared to 17%, respectively).
A second study (n 5 14) used financial incentives for
smoking cessation in which participants received $150 if
smoking cessation was confirmed at each follow-up time
point (30 days, 3 months, and 6 months). However, low
enrollment rates (24 of 114) and a high attrition rate (71%)
made it inappropriate for authors to conduct a statistical anal-
ysis of the results. This led authors to conclude that financial
incentives were ineffective as a smoking intervention in peo-
ple with head and neck cancer.22
The third study (n 5 186) used a physician-delivered and
dentist-delivered smoking cessation intervention, which com-
prised of an initial advice session and 6 booster sessions. The
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initial advice session included information on the risks of con-
tinued smoking and the benefits of cessation, a discussion of
the subject’s receptivity to quitting, a statement of confidence
in the subject’s ability to stop, 3 self-help booklets, a discus-
sion of tobacco withdrawal, a discussion to determine a target
quit date, and an affirmation of continuing provider support
during the follow-up period. The booster sessions consisted of
advice tailored to the subject’s current smoking status. At the
12-month follow-up, continuous abstinence rates were higher
in the control group (76.8%) than in the intervention group
(63.8%). Authors do not report on the P values for these
results but state that no difference was found between smoking
cessation rates in the intervention and control groups.23
3.2.6 | Effectiveness of alcohol interventions
No reduction in problem drinking, as defined by the Alcohol
Use Disorder Identification Test,24 was found in the tailored
smoking, alcohol, and depression intervention. In the inter-
vention group, 32% improved problem drinking compared to
30% in the control group.11
3.2.7 | Risk of bias
The risk of bias assessments for each study are summarized
in Table 3.11,22,23 The 2 studies that did not report
differences between intervention and control groups were
deemed to have a high risk of bias on one or more criteria.
Within the financial incentive intervention,22 the risk of
attrition bias was high, the imbalance in the number of drop-
outs between groups was found to be >10%. It also included
a small sample size, which may not have been representative
of the sample population as only those who were being
treated for premalignant conditions or had finished their
treatment over 5 years previously enrolled in the trial.22
In the physician-delivered and dentist-delivered interven-
tions, the design used a standardized version of usual care
for the control, as they found “advice-giving practices varied
widely among providers from none at all to inquiries and
warnings about smoking behavior at every visit.”23 There is
potential for contamination of the control group as it was
delivered by the same physicians as the intervention. This
might be expected to reduce the difference between the
randomized groups.
Although the combined CBT and pharmacological inter-
vention trial reported a reduction in smoking status, this
study was deemed to have an unclear risk of bias on the fol-
lowing criteria: random sequence generation, blinding, and
allocation concealment. In addition, a different measure of
smoking status was used at baseline and follow-up (smoking
status in the last 6 months at baseline compared to current
smoking status at follow-up). Unlike the 2 other studies
included in the synthesis, biochemical verification of smok-
ing status was not used, so the results rely on self-reported
data, which is at a higher risk of bias.
4 | DISCUSSION
This review synthesizes the results of smoking and alcohol
interventions in trials with people with head and neck cancer
and premalignant dysplasia in order to examine the effective-
ness of these interventions on behavioral change, QOL, and
clinical outcomes. These results show that few trials have
been conducted into smoking and alcohol interventions for
people with head and neck cancer and oral dysplasia.
Of the 3 studies included in the review, only 1 study,
using nurse-led CBT alongside pharmacologic management,
was found to have an effect on smoking status. This study
TABLE 2 Behavioral Change Technique Taxonomy codes
Reference, author,
year Taxonomy codes
Duffy et al11 2006 1.1 (goal setting); 1.2 (coping skills); 2.3
(self-monitoring); 4.1 (social skills train-
ing); 4.2 (analyzing antecedents); 11.1
(pharmacological support)
Ghosh et al22 2016 10.2 (material reward); 10.8 (outcome in-
centive)
Gritz et al23 1993 1.2 (tobacco withdrawal); 1.3 (target quit
date); 1.5 (booster session review); 1.8
(contract); 3.1 (staff support); 4.1 (tips on
how to quit); 5.1 (risks and benefits); 15.1
(statement of confidence)
TABLE 3 Assessment of risk of bias of included studies
Reference, author,
year
Sequence
generation
Allocation
concealment
Blinding of
participants and
personnel
Blinding of
outcome
assessors
Outcome
data
completeness
Outcome
reporting
Other
sources of
bias
Duffy et al11 2006 Unclear Unclear Low Unclear Low Low Unclear
Ghosh et al22 2016 Low Unclear Low Unclear High Low High
Gritz et al23 1993 Unclear Unclear Low Unclear Low Low High
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relied on self-report measures and was deemed to have an
unclear risk of bias. These results are consistent with previ-
ous findings into smoking cessation interventions in head
and neck cancer.17 The review on the effectiveness of smok-
ing cessation interventions in cessation rates in patients with
head and neck cancer included 2 of the 3 interventions we
report on11,23 as well as 1 study with a quasi-experimental
design, which tested a brief intervention with pharmacologic
management.25 As with our review, the only intervention the
reviewers identified that resulted in a difference between
groups was the CBT and pharmacologic intervention study.11
Both systematic review results are also consistent with the
findings of smoking intervention studies conducted within
the general population. One Cochrane review showed that
combining pharmacotherapy and behavioral therapy
increased cessation compared to usual care.26
Although the use of financial incentives has been found
to boost cessation rates in some populations,27 the low
recruitment and high attrition rates in the financial incentive
intervention22 may indicate that financial reward is not a
strong incentive in people with premalignant conditions or
those who have completed treatment for head and neck can-
cer. Further research could help to identify what incentives,
financial or otherwise, incite behavioral change in this popu-
lation group. Using this kind of formative research to
increase our understanding of the underlying mechanisms
that result in change in smoking status for people with head
and neck cancer and oral dysplasia, may result in the design
of more successful interventions.28 The fact that this trial
only recruited people who were being treated for prema-
lignancy or had completed treatment >5 years previously is
also of interest. The diagnosis of cancer is a health event that
could be used as a “teachable moment” to prompt or facili-
tate desired behavioral change.29 Exploring the implementa-
tion of interventions at alternative time points on the head
and neck cancer treatment pathway, such as diagnosis or
commencement of treatment, could help identify the most
effective teachable moments.
This review highlights the potential for contamination of
the control group when standardizing “usual care.” Contami-
nation can occur if healthcare providers who routinely pro-
vide support over and above that of the trial’s standard care
protocol continue to do so during the trial. Conversely,
standardization may actually increase the level of support
provided by other healthcare providers. Both of these scenar-
ios can dilute the perceived effectiveness of interventions.
This issue can be further compounded if the same healthcare
professionals are delivering both the control and intervention
conditions. Techniques for minimizing this risk of bias, such
as the use of cluster randomization,30 could be considered
for future trial design, although these may increase other
risks of bias, for example, selection bias.31
Six further smoking cessation interventions, reported in 7
papers, were identified through the literature search. How-
ever, these were not included in the qualitative narrative, as
the results were not stratified by cancer site. Similar to the
studies included in the review, no significant effects were
reported on abstinence rates and risk of bias was deemed as
unclear or high (see Supporting Information Appendices S2
and S3). Although the benefits of smoking cessation and
reducing alcohol intake for cancer survivors are well docu-
mented in observational research, few trials have been con-
ducted in patients with cancer32 and it is unclear how
cessation interventions vary depending on cancer type.33 It
would, therefore, be of benefit for future studies that recruit
participants with differing cancer types to report the differen-
ces in cancer-site-specific cessation rates.
The main strengths of our review are the systematic and
detailed search strategy used to find eligible studies and the
use of 2 reviewers to screen and extract the data. Including
people with head and neck cancer and premalignant condi-
tions in our search criteria allowed us to include interventions
that recruited both participant groups. As discussed previ-
ously, our narrative and conclusions are limited by the exclu-
sion of a number of interventions based on the inability to
extract head and neck specific data.
In summary, the paucity of data along with the unclear
reporting and risk of bias in trials conducted to date means
we are unable to draw any conclusions on the effectiveness
of smoking and alcohol interventions in people with head
and neck cancer. As there are no data from RCTs on the
effects of smoking and alcohol interventions on clinical out-
comes, such as progression-free or disease-free survival,
long-term follow-up to explore the impact of interventions
on these outcomes is required. Our review highlights that fur-
ther research is required into smoking and alcohol interven-
tions in patients with head and neck cancer and the effects
these interventions have on disease-free survival and disease
progression. Further studies could focus on formative
research into the underlying mechanisms that lead to success-
ful cessation in this population group, suitable control condi-
tions/trial design, and interventions that include both
pharmacological and behavioral therapy.
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